Coronavirus: What's happening in Canada and around the world on Thursday - CBC News | Canada News Media
Connect with us

News

Coronavirus: What's happening in Canada and around the world on Thursday – CBC News

Published

 on


The latest:

  • Ontario is dropping its tentative plan to end its vaccine passport program in mid-January, CBC News has learned.

  • Public Health Agency of Canada failed to keep tabs on most quarantine hotel stays, auditor general finds. 

  • New Brunswick sees new single-day high with 174 cases, plus two deaths.

  • In scathing report, auditor general says feds failed to protect foreign farm workers from pandemic.

  • World Health Organization warns wealthy countries again not to hoard vaccines while low-income countries go without: ‘It’s not going to work.’
     
  • Have a coronavirus question or news tip for CBC News? Email: COVID@cbc.ca

Vaccine makers are racing to update their COVID-19 shots against the newest coronavirus threat even before it’s clear a change is needed, just in case. 

Experts doubt today’s shots will become useless but say it’s critical to see how fast companies could produce a reformulated dose and prove it works — because whatever happens with omicron, this newest mutant won’t be the last.

Omicron “is pulling the fire alarm. Whether it turns out to be a false alarm, it would be really good to know if we can actually do this — get a new vaccine rolled out and be ready,” said immunologist E. John Wherry of the University of Pennsylvania.

It’s too soon to know how vaccines will hold up against omicron. The first hints this week were mixed: Preliminary lab tests suggest two Pfizer doses may not prevent an omicron infection but they could protect against severe illness. And a booster shot may rev up immunity enough to do both. 

A health-care worker administers a dose of the Pfizer-BioNTech COVID-19 vaccine to a woman during an initiative to vaccinate people 12 and over, in Lima, Peru, earlier this week. (Sebastian Castaneda/Reuters)

Better answers are expected in the coming weeks and regulators in the U.S. and other countries are keeping a close watch. The World Health Organization has appointed an independent scientific panel to advise on whether the shots need reformulating because of omicron or any other mutant.

But authorities haven’t laid out what would trigger such a drastic step: If vaccine immunity against serious illness drops, or if a new mutant merely spreads faster? 

“This is not trivial,” said Ugur Sahin, CEO of BioNTech, Pfizer’s vaccine partner, shortly before omicron’s discovery. A company could apply to market a new formula, he said, “but what happens if another company makes another proposal with another variant? We don’t have an agreed strategy.”

It’s a tough decision — and the virus moves faster than science. Just this fall the U.S. government’s vaccine advisers wondered why boosters weren’t retooled to target the extra-contagious delta variant — only to have the next scary mutant, omicron, be neither a delta descendant nor a very close cousin.

Vaccine producers aren’t starting from scratch

COVID-19 vaccines work by triggering production of antibodies that recognize and attack the spike protein that coats the coronavirus, and many are made with new technology flexible enough for easy updating.

The Pfizer and Moderna vaccines are fastest to tweak, made with genetic instructions that tell the body to make harmless copies of the spike protein — and that messenger RNA can be swapped to match new mutations.

Pfizer expects to have an omicron-specific candidate ready for U.S. regulators to consider in March, chief scientific officer Dr. Mikael Dolsten told The Associated Press.

Moderna is predicting 60 to 90 days to have an omicron-specific candidate ready for testing. 

Pfizer and Moderna already have successfully brewed experimental doses to match delta and another variant named beta, shots that haven’t been needed but offered valuable practice.

Original vaccines still offer protection

So far, the original vaccines have offered at least some cross-protection against prior variants. Even if immunity against omicron isn’t as good, Dr. Anthony Fauci, the top U.S. infectious disease expert, hopes the big antibody jump triggered by booster doses will compensate.

Pfizer’s preliminary lab testing, released Wednesday, hint that might be the case.

But antibodies aren’t the only layer of defence. Vaccines also spur T cells that can prevent serious illness if someone does get infected, and Pfizer’s first tests showed, as expected, those don’t seem to be affected by omicron.

Also, memory cells that can create new and somewhat different antibodies with each dose.

“You’re really training your immune system not just to deal better with existing variants, but it actually prepares a broader repertoire to deal with new variants,” Dolsten said.

-From The Associated Press, last updated at 5:22 p.m. ET


What’s happening across Canada

WATCH | Surge in Quebec cases mirrors last year’s, with one big difference, doctor says: 

COVID-19: When could omicron become dominant in Canada?

23 hours ago
Duration 6:56

Andrew Chang talks to infectious diseases specialists Dr. Susy Hota and Dr. Lisa Barrett about when the omicron variant may become dominant in Canada, whether it appears milder than delta and if people should change their holiday plans. 6:56

Ontario on Thursday reported 1,290 new COVID-19 cases and 10 additional deaths. In Quebec, meanwhile, health officials reported one additional death and 1,807 new cases of COVID-19.

Canada’s two most-populous provinces have been seeing an uptick in cases, sparking concern ahead of the traditionally busy holiday season.

-From CBC News, last updated at 3:06 p.m. ET


What’s happening around the world

Seats and tables of a closed café are seen during a COVID-19 lockdown in Salzburg, Austria, on Wednesday. (Leonhard Foeger/Reuters)

As of late Thursday afternoon, more than 268.4 million cases of COVID-19 had been reported worldwide, according to Johns Hopkins University’s coronavirus tracker. The reported global death toll stood at more than 5.2 million.

In Europe, the World Health Organization expressed concerns Thursday that rich countries spooked by the emergence of the omicron variant could step up the hoarding of COVID-19 vaccines and strain global supplies again, complicating efforts to stamp out the pandemic.

The UN health agency reiterated its advice to governments against the widespread use of boosters in their populations so well-stocked countries can instead send doses to low-income countries that have largely lacked access to them.

“As we head into whatever the omicron situation is going to be, there is risk that the global supply is again going to revert to high-income countries hoarding vaccine to protect — in a sense, in excess — their opportunity for vaccination,” said Dr. Kate O’Brien, head of WHO’s department of immunization, vaccines and biologicals.

“It’s not going to work. It’s not going to work from an epidemiological perspective, and it’s not going to work from a transmission perspective unless we actually have vaccine going to all countries, because where transmission continues, that’s where the variants are going to come from.”

In Austria, the health minister announced plans Thursday to impose fines of up to €3,600 (more than $5,100 Cdn) on people who flout a vaccine mandate which will be introduced in February for all residents 14 and over.

The government announced last month that it would implement a general vaccine mandate early next year, becoming the first European country to do so.

Slovakia, meanwhile, will give cash handouts to people over 60 who get vaccinated or have their booster shot, aiming to spur inoculation rates lagging behind others in the EU.

In the Americas, U.S. authorities expanded eligibility for booster shots to several million 16- and 17-year-olds.

Cuba detected its first omicron case in a person who had travelled from Mozambique, Cuban state media agency ACN reported.

In Africa, South Africa, where the omicron coronavirus variant is driving a fourth wave of COVID-19 infections, has seen a 255 per cent increase in infections in the past seven days, but only six per cent of intensive care beds are occupied by COVID-19 patients, WHO Africa official Thierno Balde said on Thursday.

Melva Mlambo, right, and Puseletso Lesofi, both medical scientists, prepare to sequence omicron samples at the Ndlovu Research Center in Elandsdoorn, South Africa, on Wednesday. The centre is part of the Network for Genomic Surveillance in South Africa, which discovered the omicron variant. (Jerome Delay/The Associated Press)

Just 7.5 per cent of more than one billion people in Africa have had initial vaccine shots.

In the Asia-Pacific region, Indian COVID-19 vaccine makers are lobbying the government to authorize boosters as supplies have outstripped demand.

Meanwhile, Pakistan is investigating its first possible case of the omicron variant.

Several parent associations in South Korea held protests against a vaccine pass mandate for children aimed at containing the spread of COVID-19 among teenagers.

In the Middle East, health officials in Iran on Thursday reported 3,228 new cases of COVID-19 and 78 additional deaths.

-From Reuters, The Associated Press and CBC News, last updated at 5:34 p.m. ET

Adblock test (Why?)



Source link

Continue Reading

News

STD epidemic slows as new syphilis and gonorrhea cases fall in US

Published

 on

 

NEW YORK (AP) — The U.S. syphilis epidemic slowed dramatically last year, gonorrhea cases fell and chlamydia cases remained below prepandemic levels, according to federal data released Tuesday.

The numbers represented some good news about sexually transmitted diseases, which experienced some alarming increases in past years due to declining condom use, inadequate sex education, and reduced testing and treatment when the COVID-19 pandemic hit.

Last year, cases of the most infectious stages of syphilis fell 10% from the year before — the first substantial decline in more than two decades. Gonorrhea cases dropped 7%, marking a second straight year of decline and bringing the number below what it was in 2019.

“I’m encouraged, and it’s been a long time since I felt that way” about the nation’s epidemic of sexually transmitted infections, said the CDC’s Dr. Jonathan Mermin. “Something is working.”

More than 2.4 million cases of syphilis, gonorrhea and chlamydia were diagnosed and reported last year — 1.6 million cases of chlamydia, 600,000 of gonorrhea, and more than 209,000 of syphilis.

Syphilis is a particular concern. For centuries, it was a common but feared infection that could deform the body and end in death. New cases plummeted in the U.S. starting in the 1940s when infection-fighting antibiotics became widely available, and they trended down for a half century after that. By 2002, however, cases began rising again, with men who have sex with other men being disproportionately affected.

The new report found cases of syphilis in their early, most infectious stages dropped 13% among gay and bisexual men. It was the first such drop since the agency began reporting data for that group in the mid-2000s.

However, there was a 12% increase in the rate of cases of unknown- or later-stage syphilis — a reflection of people infected years ago.

Cases of syphilis in newborns, passed on from infected mothers, also rose. There were nearly 4,000 cases, including 279 stillbirths and infant deaths.

“This means pregnant women are not being tested often enough,” said Dr. Jeffrey Klausner, a professor of medicine at the University of Southern California.

What caused some of the STD trends to improve? Several experts say one contributor is the growing use of an antibiotic as a “morning-after pill.” Studies have shown that taking doxycycline within 72 hours of unprotected sex cuts the risk of developing syphilis, gonorrhea and chlamydia.

In June, the CDC started recommending doxycycline as a morning-after pill, specifically for gay and bisexual men and transgender women who recently had an STD diagnosis. But health departments and organizations in some cities had been giving the pills to people for a couple years.

Some experts believe that the 2022 mpox outbreak — which mainly hit gay and bisexual men — may have had a lingering effect on sexual behavior in 2023, or at least on people’s willingness to get tested when strange sores appeared.

Another factor may have been an increase in the number of health workers testing people for infections, doing contact tracing and connecting people to treatment. Congress gave $1.2 billion to expand the workforce over five years, including $600 million to states, cities and territories that get STD prevention funding from CDC.

Last year had the “most activity with that funding throughout the U.S.,” said David Harvey, executive director of the National Coalition of STD Directors.

However, Congress ended the funds early as a part of last year’s debt ceiling deal, cutting off $400 million. Some people already have lost their jobs, said a spokeswoman for Harvey’s organization.

Still, Harvey said he had reasons for optimism, including the growing use of doxycycline and a push for at-home STD test kits.

Also, there are reasons to think the next presidential administration could get behind STD prevention. In 2019, then-President Donald Trump announced a campaign to “eliminate” the U.S. HIV epidemic by 2030. (Federal health officials later clarified that the actual goal was a huge reduction in new infections — fewer than 3,000 a year.)

There were nearly 32,000 new HIV infections in 2022, the CDC estimates. But a boost in public health funding for HIV could also also help bring down other sexually transmitted infections, experts said.

“When the government puts in resources, puts in money, we see declines in STDs,” Klausner said.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Source link

Continue Reading

News

World’s largest active volcano Mauna Loa showed telltale warning signs before erupting in 2022

Published

 on

 

WASHINGTON (AP) — Scientists can’t know precisely when a volcano is about to erupt, but they can sometimes pick up telltale signs.

That happened two years ago with the world’s largest active volcano. About two months before Mauna Loa spewed rivers of glowing orange molten lava, geologists detected small earthquakes nearby and other signs, and they warned residents on Hawaii‘s Big Island.

Now a study of the volcano’s lava confirms their timeline for when the molten rock below was on the move.

“Volcanoes are tricky because we don’t get to watch directly what’s happening inside – we have to look for other signs,” said Erik Klemetti Gonzalez, a volcano expert at Denison University, who was not involved in the study.

Upswelling ground and increased earthquake activity near the volcano resulted from magma rising from lower levels of Earth’s crust to fill chambers beneath the volcano, said Kendra Lynn, a research geologist at the Hawaiian Volcano Observatory and co-author of a new study in Nature Communications.

When pressure was high enough, the magma broke through brittle surface rock and became lava – and the eruption began in late November 2022. Later, researchers collected samples of volcanic rock for analysis.

The chemical makeup of certain crystals within the lava indicated that around 70 days before the eruption, large quantities of molten rock had moved from around 1.9 miles (3 kilometers) to 3 miles (5 kilometers) under the summit to a mile (2 kilometers) or less beneath, the study found. This matched the timeline the geologists had observed with other signs.

The last time Mauna Loa erupted was in 1984. Most of the U.S. volcanoes that scientists consider to be active are found in Hawaii, Alaska and the West Coast.

Worldwide, around 585 volcanoes are considered active.

Scientists can’t predict eruptions, but they can make a “forecast,” said Ben Andrews, who heads the global volcano program at the Smithsonian Institution and who was not involved in the study.

Andrews compared volcano forecasts to weather forecasts – informed “probabilities” that an event will occur. And better data about the past behavior of specific volcanos can help researchers finetune forecasts of future activity, experts say.

(asterisk)We can look for similar patterns in the future and expect that there’s a higher probability of conditions for an eruption happening,” said Klemetti Gonzalez.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

News

Waymo’s robotaxis now open to anyone who wants a driverless ride in Los Angeles

Published

 on

 

Waymo on Tuesday opened its robotaxi service to anyone who wants a ride around Los Angeles, marking another milestone in the evolution of self-driving car technology since the company began as a secret project at Google 15 years ago.

The expansion comes eight months after Waymo began offering rides in Los Angeles to a limited group of passengers chosen from a waiting list that had ballooned to more than 300,000 people. Now, anyone with the Waymo One smartphone app will be able to request a ride around an 80-square-mile (129-square-kilometer) territory spanning the second largest U.S. city.

After Waymo received approval from California regulators to charge for rides 15 months ago, the company initially chose to launch its operations in San Francisco before offering a limited service in Los Angeles.

Before deciding to compete against conventional ride-hailing pioneers Uber and Lyft in California, Waymo unleashed its robotaxis in Phoenix in 2020 and has been steadily extending the reach of its service in that Arizona city ever since.

Driverless rides are proving to be more than just a novelty. Waymo says it now transports more than 50,000 weekly passengers in its robotaxis, a volume of business numbers that helped the company recently raise $5.6 billion from its corporate parent Alphabet and a list of other investors that included venture capital firm Andreesen Horowitz and financial management firm T. Rowe Price.

“Our service has matured quickly and our riders are embracing the many benefits of fully autonomous driving,” Waymo co-CEO Tekedra Mawakana said in a blog post.

Despite its inroads, Waymo is still believed to be losing money. Although Alphabet doesn’t disclose Waymo’s financial results, the robotaxi is a major part of an “Other Bets” division that had suffered an operating loss of $3.3 billion through the first nine months of this year, down from a setback of $4.2 billion at the same time last year.

But Waymo has come a long way since Google began working on self-driving cars in 2009 as part of project “Chauffeur.” Since its 2016 spinoff from Google, Waymo has established itself as the clear leader in a robotaxi industry that’s getting more congested.

Electric auto pioneer Tesla is aiming to launch a rival “Cybercab” service by 2026, although its CEO Elon Musk said he hopes the company can get the required regulatory clearances to operate in Texas and California by next year.

Tesla’s projected timeline for competing against Waymo has been met with skepticism because Musk has made unfulfilled promises about the company’s self-driving car technology for nearly a decade.

Meanwhile, Waymo’s robotaxis have driven more than 20 million fully autonomous miles and provided more than 2 million rides to passengers without encountering a serious accident that resulted in its operations being sidelined.

That safety record is a stark contrast to one of its early rivals, Cruise, a robotaxi service owned by General Motors. Cruise’s California license was suspended last year after one of its driverless cars in San Francisco dragged a jaywalking pedestrian who had been struck by a different car driven by a human.

Cruise is now trying to rebound by joining forces with Uber to make some of its services available next year in U.S. cities that still haven’t been announced. But Waymo also has forged a similar alliance with Uber to dispatch its robotaxi in Atlanta and Austin, Texas next year.

Another robotaxi service, Amazon’s Zoox, is hoping to begin offering driverless rides to the general public in Las Vegas at some point next year before also launching in San Francisco.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version